
    
      PRIMARY OBJECTIVE:

      I. To examine the safety and feasibility of perioperative testosterone replacement (TR)
      therapy in hypogonadal male patients undergoing major operations.

      OUTLINE: Patients are assigned to 1 of 2 arms.

      ARM I: Patients with low testosterone levels receive testosterone cypionate intramuscularly
      (IM) once a week (QW) for 3 months in the absence of disease progression or unacceptable
      toxicity.

      ARM II: Patients with normal testosterone levels receive standard peri-operative care.
    
  